Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

NCT06827990 · View on ClinicalTrials.gov ↗

Study Summary

To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.

Conditions Studied

Interventions

  • DEVICE GORE® Ascending Stent Graft (ASG device)

Study Locations (13)

Ohio

  • Cleveland Clinic — Cleveland
  • Ohio Health Research Institute — Columbus

Texas

  • The Methodist Hospital Houston — Houston
  • Baylor Research Institute — Plano

Alabama

  • University of Alabama at Birmingham — Birmingham

Florida

  • University of Florida — Gainesville

Georgia

  • Emory University School of Medicine — Atlanta

Illinois

  • Northwestern Medicine — Chicago

Indiana

  • Indiana University — Indianapolis

Massachusetts

  • Massachusetts General Hospital — Boston

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2025-09-22
Est. Completion 2031-09-01
Phase NA

Sponsor

W.L.Gore & Associates

117 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06827990

The ClinicalTrials.gov registry entry for NCT06827990 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 117 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Aortic Dissection appearing as the primary indexed condition, and to 1 intervention — of which GORE® Ascending Stent Graft (ASG device) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06827990 reports 13 study locations spanning 11 distinct geographic areas — top geographies include Ohio, Texas, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06827990 about?

NCT06827990 is a clinical study titled "GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections". To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.

What is the current status of trial NCT06827990?

This trial is currently recruiting. It is a NA study. The enrollment target is 112 participants. The study started on 2025-09-22. Estimated completion is 2031-09-01.

What conditions does trial NCT06827990 study?

This clinical trial studies the following conditions: Aortic Dissection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06827990?

The interventions under investigation include: GORE® Ascending Stent Graft (ASG device) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06827990?

This trial is sponsored by W.L.Gore & Associates, which has 117 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06827990 being conducted?

This trial has 13 study locations across Alabama, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial